EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DNMT2‐m5C‐ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation‐Mediated Notch Pathway

Shiguang Yang, Jie Li, Shengwei Mao, Xuhui Zhao, Douwaner Liu, Jiafeng Chen, Jialu Fu, Yichao Bu, Xiaoling Wu, Shaoqing Liu, Qifeng Yu, Qiongzhu Dong und 3 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202515931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Shiguang Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery and Liver Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion, Liver Cancer Institute, Zhongsha…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Quinolines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Clinical research projects of Zhongshan Hospital Affiliated to Fudan University, Youth Fund of Zhongshan Hospital Affiliated to Fudan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lenvatinib serves as a first‐line therapy for advanced hepatocellular carcinoma (HCC), but its clinical efficacy is severely limited by acquired drug resistance. Consequently, the identification of therapeutic targets to reverse lenvatinib resistance may offer novel strategies to achieve enhanced and durable treatment responses. In this study, a global elevation in the levels of m5C modification is observed in lenvatinib‐resistant cells compared with their parental counterparts. DNA methyltransferase 2(DNMT2), functioning as an RNA methyltransferase, is markedly upregulated in lenvatinib‐resistant specimens and correlated with poor patient survival outcomes. Both in vitro and in vivo experiments indicated that DNMT2 downregulation effectively overcame lenvatinib resistance by reducing HCC cell proliferation and promoting apoptosis, thereby restoring drug sensitivity. Mechanistically, DNMT2 functioned together with Y‐box binding protein 1 (YBX1) to stabilize downstream adenosine triphosphate citrate lyase (ACLY) mRNA through m5C modification. This process activated the Notch signaling pathway by increasing intracellular acetyl‐CoA levels and promoting histone acetylation, driving the progression of lenvatinib resistance. Critically, pharmacological inhibition of ACLY combined with lenvatinib treatment enhanced the therapeutic efficacy against HCC and could reduce the tumor burden in multiple preclinical models. Collectively, the findings indicate the importance of the DNMT2‐ACLY‐NOTCH signaling axis in lenvatinib resistance and propose novel combinatorial therapies to improve HCC treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsQuinolinesDrug Resistance, NeoplasmReceptors, NotchHistonesHumansAnimalsMiceSignal TransductionAcetylationCell Line, TumorCell ProliferationMice, NudeAntineoplastic Agents

Stichwörter der Autor:innen

hepatocellular carcinomahistone acetylationlenvatinib resistancem5C modification

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesReceptors, NotchHistonesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery and Liver Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer, Minhang Hospital, Fudan University, Shanghai, China.
  • National Clinical Research Center for Interventional Medicine, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Radiation Oncology, Huadong Hospital, Fudan University, Shanghai, China.
  • Department of Breast Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
  • Department of Hepatobiliary Surgery, Zhoushan Hospital, Zhoushan, China.

ORCID-Profile: Yinghong Shi

Förderung

  • National Natural Science Foundation of China
  • Clinical research projects of Zhongshan Hospital Affiliated to Fudan University
  • Youth Fund of Zhongshan Hospital Affiliated to Fudan University

Zitieren

APA

Yang, S., Li, J., Mao, S., Zhao, X., Liu, D., Chen, J., Fu, J., Bu, Y., Wu, X., Liu, S., Yu, Q., Dong, Q., Tang, Z., Fang, Y., & Shi, Y. (2026). DNMT2‐m5C‐ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation‐Mediated Notch Pathway. Advanced Science. https://doi.org/10.1002/advs.202515931

Vancouver

Yang S, Li J, Mao S, Zhao X, Liu D, Chen J, et al. DNMT2‐m5C‐ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation‐Mediated Notch Pathway. Advanced Science. 2026. doi:10.1002/advs.202515931

BibTeX
@article{Yang2026,
  author = {Yang, Shiguang and Li, Jie and Mao, Shengwei and Zhao, Xuhui and Liu, Douwaner and Chen, Jiafeng and Fu, Jialu and Bu, Yichao and Wu, Xiaoling and Liu, Shaoqing and Yu, Qifeng and Dong, Qiongzhu and Tang, Zheng and Fang, Yuan and Shi, Yinghong},
  title = {DNMT2‐m5C‐ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation‐Mediated Notch Pathway},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202515931}
}
Kostenlos starten →